Project Grant R01HL179122
Award Date 9/9/25
Completion Date 5/31/29
Dollars Obligated $650K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
- This federal Project Grant award of $621,546.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), focuses on observing the single molecule dynamics of the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) under both normal and disease-associated conditions. The primary objectives are to: 1) Engineer a single-walled carbon nanotube field effect transistor (SWNT FET) system to record PKA-C single molecule...
- The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), awarded a $699,133 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The project aims to investigate the molecular insights into the actions of SGLT2 inhibitors and GLP1 agonists across the heart,...
- This Project Grant award for $727,710.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to advance understanding of the mechanisms driving arrhythmogenic cardiomyopathy, a genetic heart disease that can cause sudden death in young people. The award supports research at the University of California, San Diego (UCSD) to develop preclinical mouse models exhibiting inflammation and T-cell mediated immune responses as key drivers of this...
- This $761,152 project grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of California, San Diego (UCSD) to investigate the gene regulatory mechanisms controlling the expression of cardiac myosin heavy chain proteins. The goal is to understand how shifts in the ratio of the MYH6 and MYH7 isoforms impact cardiac contractility, which is critical for heart function under both normal and disease...
- This federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the use of NNMT inhibition to treat heart failure. The $736,089 grant supports research to determine if increased NNMT activity, leading to NAD+ deficiency, is central to the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $507,096.00 to Wake Forest University Health Sciences (WFUHS) to conduct research on cellular heterogeneity in mitochondrial calcium dynamics in heart failure, with a focus on heart failure with preserved ejection fraction (HFPEF). The key products and services to be delivered under this 5-year award include: 1) Characterizing heart cell-specific...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...